P rotein kinase C (PKC) is a key enzyme in signal transduction involved in a variety of cellular functions. 1 PKC plays a major role in cardioprotection from ischemia/reperfusion injury in various cell culture studies and animal models. [2] [3] [4] Multiple PKC isozymes are expressed in the heart. 5, 6 The role of individual isozymes in cardioprotection has been difficult to assess because the pharmacological tools currently available are not isozyme selective.
We previously developed several PKC translocation inhibitor and activator peptides that, when introduced into cells, cause selective regulation of translocation and function of the corresponding PKC isozymes. 7 These peptides were designed on the basis of the observation that isozyme-unique functions are mediated by binding of each isozyme to its corresponding selective anchoring protein, receptor for activated C-kinase (RACK), each localized to a selective subcellular site. 5, 8, 9 More recently, we showed that the Tat protein-derived peptide provides a means to deliver the PKC-regulating peptides into cardiomyocytes when infused through the coronary arteries. 10 Using this peptide delivery technique, we showed that pretreatment with the ␦-PKC inhibitor peptide ␦V1-1 or the ⑀-PKC activator peptide ⑀RACK reduced the damage of isolated adult rat cardiomyocytes and of isolated perfused mouse and rat hearts from simulated ischemia. 10 -12 In the present study, we determined whether the time at which each of these PKC-regulating peptides is delivered affects induced cardioprotection, the effects of these peptides in acute (Tatconjugated peptide) and chronic (transgenic mice) administration, and the effect of treatment with both peptides on cardioprotection from ischemia/reperfusion damage in isolated hearts.
Methods

Peptide Synthesis
We synthesized ␦V1-1 (␦-PKC inhibitor, amino acids 8 to 17
[SFNSYELGSL]) 10 13 via a cysteine-cysteine S-S bond at their N termini, as previously described. 14 
Isolated Perfused Rat Heart Model
Wistar rats (300 to 350 g) were heparinized (2000 U/kg IP) and then anesthetized with sodium pentobarbital (100 mg/kg IP). The hearts were rapidly excised and then perfused with an oxygenated KrebsHenseleit solution containing (in mmol/L) NaCl 120, KCl 5.8, NaHCO 3 25, NaH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 1.0, and dextrose 10, pH 7.4, at 37°C in a Langendorff coronary perfusion system. The coronary flow rate was kept constant during the experiment at 10 mL/min. A thin latex balloon filled with water was inserted into the left ventricular (LV) cavity and connected to a pressure transducer (PowerLab/8SP, AD Instruments) for measurement of the isovolumic LV pressure. The LV volume was adjusted initially at an end-diastolic pressure (EDP) of 3 to 5 mm Hg. Hearts were paced at 3.3 Hz (200 bpm) with a bipolar pacing catheter. Hearts were submerged into a heat-jacketed organ bath set at 37°C. Coronary effluent was collected to determine creatine phosphokinase (CPK) release. After Ն10 minutes of equilibration, the experiment began, and the LV pressure and coronary perfusion pressure were monitored throughout the experiment.
Experimental Protocol in Isolated Perfused Rat Hearts
Hearts were subjected to a 20-minute global ischemia and a 30-minute full reperfusion to measure functional recovery and CPK release during reperfusion. (Sets 1 to 3 in Figures 1 to 3 ) or a 40-minute global ischemia and a 120-minute full reperfusion to measure infarct size after ischemia/reperfusion (Set 4 in Figure 4 ). In the first set of experiments, the hearts were perfused with Tat peptide conjugated to ␦V1-1 (␦V1-1), Tat peptide conjugated to ⑀RACK (⑀RACK), Tat peptide alone, or vehicle during the first 10 or 20 minutes of reperfusion at the indicated concentration (Յ500 nmol/L; Set 1 in Figure 1 ). In the second set of experiments, the hearts were perfused with ␦V1-1, ⑀RACK, scrambled ⑀RACK, or vehicle for 10 minutes with or without a peptide-washout period of 10 minutes before ischemia (Set 2 in Figure 2 ). In the third and fourth sets of experiments, the hearts were perfused with either ␦V1-1 (500 nmol/L), ⑀RACK (500 nmol/L), Tat peptide (500 nmol/L), or vehicle for 10 minutes before ischemia and for 20 minutes during reperfusion or with ⑀RACK (500 nmol/L) for 10 minutes before ischemia and then with ␦V1-1 (500 nmol/L) for 20 minutes during reperfusion (Sets 3 and 4 in Figures 3 and 4) .
Histomorphometry
At the end of the reperfusion period, hearts were sliced into 1-mm-thick transverse sections and incubated in triphenyltetrazolium chloride solution (1% in phosphate buffer, pH 7.4) at 37°C for 15 minutes as reported previously. 15 Infarct size was expressed as a percentage of the risk zone (equivalent to total LV muscle mass).
Transgenic Mice
Details of transgenic mice (FVB/N background) expressing the ␦-PKC inhibitor (␦V1) and ⑀-PKC activator (⑀RACK) under control of the ␣-myosin heavy chain promoter have been described previously. 11, 16, 17 The ␦V1 transgene expression was under the attenuated promoter TRE-2, 16 and the morphometric or hemodynamic characteristics of these transgenic mice have been described previously. 16 Compound transgenic mice expressing ␦V1 and ⑀RACK (⑀R/␦V1) were obtained by breeding heterozygous ␦V1 and heterozygous ⑀RACK mice. Hemodynamic and morphometric parameters in these transgenic mice as measured by echocardiographic measurements in vivo were not statistically different from those measured in nontransgenic (NTG) control animals (nϭ12 to 26). Similarly, there was no statistical difference between the ⑀R/␦V1 mice and the NTG mice when ex vivo hemodynamic measurements were used before introduction of ischemia and reperfusion. (These measurements included heart rate, LV systolic and diastolic pressures, and their derivatives.) Transgenes, alone and in combination, were identified by genomic Southern analysis of tail-clip DNA. Isolated hearts from 12-to 20-week-old mice were perfused on Langendorff apparatus for 20 minutes for equilibration, followed by a 40-minute period of no-flow ischemia and a 20-minute reperfusion period as reported previously. 10, 11, 16 Contractile function was measured as the peak rate of increase of pressure (ϩdP/dt). CPK was assayed in the perfusate during reperfusion.
Statistical Analysis
Data are expressed as mean Ϯ SEM. The main effects of the peptide were tested by 2-factor ANOVA for repeated measures in functional recovery (Figures 1 to 3 , A through C, and Figure 5A ), and differences of infarct size, total CPK release, and LV developed pressure (LVDP) at individual time points between the groups were assessed by 1-factor ANOVA with Bonferroni's multiplecomparison test. 
Results
␦-PKC Inhibitor Mediates Protection From Reperfusion Injury
When the ␦-PKC inhibitor ␦V1-1 was administered immediately after ischemia only during the reperfusion period, rat hearts exhibited improved LVDP, EDP, and coronary vascular resistance (CVR) and decreased CPK release (Figure 1 ). Even at 1 minute after the administration of this peptide, there was a significantly improved LVDP (33.9Ϯ6.4 mm Hg in ␦V1-1, 14.9Ϯ3.1 mm Hg in Tat; PϽ0.006) and CVR (9.6Ϯ0.8 in ␦V1-1, 13.3Ϯ0.6 in Tat; PϽ0.006; Figure 1 ). The effect of ␦V1-1 was specific, because the Tat carrier peptide did not have cardioprotective effects against reperfusion injury. In contrast to ␦V1-1, ⑀RACK did not improve LVDP, EDP, or CVR and did not decrease CPK release when administered only during reperfusion (Figure 1 ). ␦V1-1 conferred cardioprotection at a wide range of concentrations, from 500 pmol/L to 500 nmol/L, as measured by CPK release ( Figure 1F) . Thus, ␦V1-1 but not ⑀RACK protected cardiomyocytes and prevented the decrease of LV function when delivered during reperfusion.
Ischemic Preconditioning-Like Effects of ⑀-PKC-Selective Activator
When ⑀RACK and ␦V1-1 were administered before ischemia and were not removed by washing, these peptides significantly improved LVDP and CVR and decreased CPK release during reperfusion (Figure 2 ). To test whether either of these peptides mimicked preconditioning, we followed peptide administration with a 10-minute washout before ischemia. ␦V1-1 exhibited no cardioprotection when administered before ischemia followed by a 10-minute washout period preceding the ischemia (Figure 2, E and F) . In contrast, ⑀RACK treatment significantly protected cardiomyocytes even when the peptide was washed out before ischemia ( Figure 2 , E and F). As expected, the inactive form of ⑀RACK, scrambled ⑀RACK, did not have a significant cardioprotective effect (Figure 2) . Thus, ⑀RACK but not ␦V1-1 had an ischemic preconditioning-like effect; ⑀RACK administration provides cardioprotection when given before the ischemic event.
Enhanced Cardioprotection From Ischemia/Reperfusion Damage by Combined Treatment With the ⑀-PKC Activator and the ␦-PKC Inhibitor
Because ␦V1-1 was cardioprotective when delivered during reperfusion and ⑀RACK was cardioprotective when delivered before the ischemic period, we hypothesized that combined treatment with ␦V1-1 and ⑀RACK would yield an additive benefit. When we administered ⑀RACK before ischemia and ␦V1-1 during reperfusion, there was a greater functional recovery after ischemia/reperfusion compared with treatment with each peptide alone (Figure 3 ). Although treatment with either peptide limits the infarct size to 50% to 60% of the untreated control or Tat carrier peptide, treatment with both peptides reduced infarct size by an additional 20% (Figure 4) . Thus, ␦-PKC inhibitor and ⑀-PKC activator mediate cardioprotection by regulating ischemia/reperfusion damage at distinct time points of the process, and their therapeutic effect is additive. 
Cardioprotective Effects of ␦-PKC Inhibitor and ⑀-PKC Activator in Transgenic Mouse Hearts
Treatments with the ␦-PKC inhibitor and ⑀-PKC activator improved both cardiac function and CVR in isolated perfused rat hearts, suggesting effects of the PKC regulators on both endothelial cells and cardiac myocyte cells. To determine whether cardioprotection can occur when the PKC regulators are present only in cardiac myocytes, we used transgenic mice that express PKC regulators selectively only in these cells. To this end, we constructed transgenic mice expressing ␦V1, ⑀RACK, or both ␦V1 and ⑀RACK (⑀R/␦V1 compound mice) using the cardiac myocyte-specific ␣-myosin heavy chain promoter. 11, 16, 17 The transgenic mice had a low number of copies of the PKC regulators and exhibited normal morphometric and hemodynamic characteristics as measured by echocardiography in vivo and by studies of isolated perfused hearts ex vivo (data not shown). After subjecting these mice to ischemia/reperfusion, we found that the expression of ␦V1, ⑀RACK, or ⑀R/␦V1 in the myocytes improved cardiac function significantly during reperfusion compared with NTG ( Figure 5A ). Although functional recovery of the 3 groups of transgenic mice was similar, when muscle damage as measured by CPK release was assessed, concomitant inhibition of ␦-PKC and activation of ⑀-PKC in cardiomyocytes provided additive protection from ischemia and reperfusion compared with regulating each PKC alone (Figure 5B ). In addition, because the expression of the PKC regulators was restricted to the cardiac myocytes, we can conclude that substantial cardiac protection from ischemia and reperfusion damage can be obtained by selectively regulating PKC isozymes in the myocytes only.
Discussion
In this study, we used rationally designed selective PKC isozyme regulator peptides conjugated to Tat carrier peptide to determine the role of PKC isozymes in ischemia/reperfusion injury. We found that (1) the ␦-PKC inhibitor has cardioprotective effects against reperfusion injury, (2) the ⑀-PKC activator has ischemic preconditioning-like effects, (3) combined treatment with an ⑀-PKC activator before ischemia and ␦-PKC inhibitor at the onset of reperfusion induces a greater cardioprotective effect against ischemia/ reperfusion injury than the treatment with each peptide alone, and (4) the selective expression of ␦-PKC inhibitor or ⑀-PKC activator only in cardiomyocytes protects cardiomyocytes directly against ischemia/reperfusion injury and the coexpres- Cardioprotection against ischemia/reperfusion injury by combined treatment with ␦V1-1 and ⑀RACK (effect on infarct size). ⑀RACK peptide was administered before ischemia, and then ␦V1-1 peptide was administered at onset of reperfusion. Effects of this treatment protocol were compared with treatment with 1 peptide (Tat carrier, ␦V1-1, or ⑀RACK) administered both before ischemia and at onset of reperfusion, respectively. *PϽ0.005 vs No peptide, †PϽ0.005 vs Tat, ¶PϽ0.005 vs ⑀RACK, ‡PϽ0.005 vs ␦V1-1. nϭ4 for each group.
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Cardioprotection by PKC Translocation Regulatorssion of both these PKC regulators in cardiomyocytes yields an additive benefit as determined by reduction in muscle damage. The preconditioning-like effect induced by ⑀RACK is predicted from previous studies. 10 -12 However, the finding that effective cardioprotection is achieved when ␦V1-1 is delivered only during reperfusion suggests that, as predicted by Bolli, 18 a substantial amount of cardiac damage occurs during reperfusion only. Our data here indicate that ␦-PKC activity mediates reperfusion damage at least in part because inhibition of ␦-PKC immediately at the onset of reperfusion can decrease cardiac damage by Ͼ50%.
The Role of ␦-PKC in Reperfusion Injury
The molecular basis of ␦-PKC in reperfusion injury is not known. Recently, the involvement of apoptosis in ischemia/ reperfusion injury has been demonstrated in a number of species, including humans. 19 -21 In experimental ischemia/ reperfusion models, although apoptosis may be initiated during ischemia, the number of apoptotic cells is increased during reperfusion, and apoptosis may actually be accelerated by the process of reperfusion. 20, 21 These observations suggest that the apoptotic component contributes particularly to the death of the myocardium during reperfusion. In vitro overexpression of ␦-PKC is associated with inhibition of proliferation, cell cycle arrest, enhanced differentiation, and/or accelerated apoptosis in several nonheart cell lines. 22 Thus, the cardioprotective effects of a ␦-PKC inhibitor may result from preventing cell death by modifying cellular signaling involving this isozyme in apoptosis. Scarabelli et al 23 reported that in the very early stages of reperfusion, apoptosis is first seen in the endothelial cells of small coronary vessels and then spreads in a radial fashion to the surrounding cardiac myocytes in isolated perfused rat hearts. We observed cardioprotection when the peptide was applied through the coronary artery; thus, the peptide can act on all heart cells, including endothelial cells. Cardioprotection was also observed in mice expressing the ␦-PKC inhibitor in their myocytes (previous study 16 and this study). Therefore, it appears possible that cardioprotection by ␦V1-1 is a result of its effects both on cardiomyocytes and on endothelial cells. How ␦-PKC is activated during reperfusion is also unclear. Recent data on the role of endothelin A in this process provide a possible explanation. The level of endothelin increases in plasma and myocardial tissue during ischemia/ reperfusion, 24 resulting in direct vascular and myocardial damage. 25 Moreover, treatment with an endothelin A antagonist significantly limits the progressive decrease in postischemic microvascular reflow and decreases the infarct size when given at the time of reperfusion. 26 Endothelin-1 induces the translocation of ␦-PKC from soluble to particulate fractions in neonatal rat ventricular cardiomyocytes. 27 Thus, if translocation of ␦-PKC is induced by endothelin during reperfusion, ␦-PKC may mediate the endothelin-induced damage.
PKC and Ischemia/Reperfusion Injury
The hypothesis that the translocation of PKC plays a key role in ischemic preconditioning is supported by many studies. However, which isozyme mediates this effect is still controversial. Ping et al 28 reported that ⑀-PKC and -PKC translocate selectively to the particulate fraction in rabbit myocardium after several cycles of brief coronary occlusion/ reperfusion. Translocation of ␦-PKC and ⑀-PKC is induced by ischemic preconditioning in neonatal rat cultured cardiomyocytes 2 and in rat whole hearts. 29 These data correlated translocation of different PKC isozymes with preconditioning and suggested that the role of PKC isozymes may differ in various animal species. However, we found that the ⑀-PKC activator, ⑀RACK, alone conferred cardioprotective effects against ischemia/reperfusion in rats and mice 10 -12 and that the ⑀-PKC inhibitor inhibited cardiac protective effects induced by ischemic preconditioning in mice, rats, and rabbits. 3, 10, 30 In addition, Ping and coworkers demonstrated cardioprotection from ischemia/reperfusion of transgenic mice overexpressing ⑀-PKC. 31 Moreover, another report demonstrated loss of ischemic preconditioning in ⑀-PKC-knockout mice. 32 Our findings that ⑀RACK can be washed away before the ischemic event and still confer cardiac protection from ischemia are in agreement with ⑀-PKC as a trigger for the preconditioning effect. 2 In contrast to our data, some earlier studies suggested that ␦-PKC plays a cardioprotective role in ischemic preconditioning. 33, 34 Kawamura et al 33 showed that ischemic preconditioning under low-Ca 2ϩ perfusion induced translocation of ␦-PKC but not ⑀-PKC, which was correlated with improved cardiac function after ischemia/reperfusion in isolated rat heart. They also showed that although the treatment of bisindolylmaleimide (PKC inhibitor) before preconditioning inhibited translocation of ␦-PKC but not ⑀-PKC after preconditioning, this inhibitor did not prevent the cardioprotection of preconditioning. 33 These data indicate that the effects of preconditioning are mediated by either ␦-PKC or ⑀-PKC. Zhao et al 34 showed that the protective effect of the constitutively active ␦-PKC can be transmitted to cocultured nontransfected myocytes. They suggest that ⑀-PKC activation may be induced by ␦-PKC-mediated in- creased release of adenosine and activation of PKC via the A 1 adenosine receptors. 35 The present study showed that pretreatment with an ⑀-PKC activator followed by washout before ischemia/reperfusion conferred cardioprotection. We also showed that concomitant treatment with both PKC regulators provides superior protection compared with each regulator alone. Because here, we used isozyme-selective pharmacological tools and regulated the function of the endogenous enzyme, the simplest explanation of our data is that ⑀-PKC activation before ischemia protects the heart by mimicking preconditioning, whereas inhibition of ␦-PKC during reperfusion protects the heart from reperfusion damage.
